Screening for gestational diabetes mellitus: the Sri Lankan experience

CN Wijeyaratne¹, S Ginige², A Arasalingam³, C Egodage³ and K Wijewardhena⁴

(Index words: Community screening, OGTT cut-off values)

Abstract

Objective To evaluate tests used for screening and confirmation of gestational diabetes mellitus (GDM) in Sri Lanka.

Methods Field based: Consecutive pregnant women in Homagama DDHS area (n = 853), were assessed for risk factors and subjected to random and postprandial urinary Benedict’s and Dipstick® tests, fasting and 2 hour post 75 g glucose capillary blood glucose (FBG and 2 hBG) which were validated against 75 g oral glucose tolerance test (OGTT) performed at 24–28 weeks (WHO criteria).

Hospital based: Retrospective analysis of consecutive high-risk women (n = 999) and prospective study of randomly selected GDM women (n = 66) to assess predictive value of the OGTT.

Results Field based: Sensitivity and specificity respectively of random urine Benedict’s, 10%, 99.2%; postprandial urine Benedict’s, 52.2%, 94.5%; postprandial urine Dipstick®, 68.7%, 90%; capillary FBG threshold 4.1 mmol/l, 62.6%, 73%; capillary 2 hBG threshold 7.2 mmol/l, 98.5%, 95.2%; risk factors, 93.1%, 22.2%.

Hospital based: OGTT–11.6% lag curves, 16.3% abnormal, FPG accuracy at 4.7 mmol/l; predictive value of 2 hPG ≥8.9 mmol/l for insulin treatment—sensitivity 97.2%, specificity 71.4%.

Conclusions Current practice of random urine testing in community screening for gestational diabetes is unreliable, and glucose specific postprandial urine test improves sensitivity. FPG is unsuitable for screening, the 2 hour post 75 g blood glucose at a threshold of >7.2 mmol/l is sensitive and specific. In laboratory confirmation using 75 g OGTT the fasting plasma glucose has low predictive value, 2 hour test performed alone is liable to false positives and 2 hour glucose >8.9 mmol/l following a peak at 1 hour suggests the need for insulin treatment.

Introduction

Gestational diabetes mellitus (GDM) is defined as carbohydrate intolerance resulting in hyperglycaemia of variable severity, with onset or first recognition during pregnancy, and irrespective of whether or not insulin is required or the condition persists after pregnancy [1–3]. There is a rise in the prevalence of GDM in Sri Lanka. We reported from a community based assessment in 2003 that the age standardized prevalence was 10.3% [4], which is in keeping with global trends of increasing obesity, type 2 diabetes mellitus and GDM [5]. In our current practice, pregnant women who meet the WHO diagnostic criteria for diabetes mellitus or impaired glucose tolerance (IGT) following a 75 g oral glucose tolerance test (OGTT) are classified as having GDM. However, much confusion surrounds screening for glucose intolerance during pregnancy in terms of who should be screened, how to screen, and the management of those with positive screening tests. There has been no large scale, well designed, community based study to determine optimal screening for GDM in Sri Lanka. The maternal and child health (MCH) programme in Sri Lanka needs to be recommended a suitable screening test for implementation through its prevailing infrastructure to enable universal screening for GDM, where the screening test positive subjects need to be subjected to the diagnostic OGTT. Furthermore, the predictive value of the diagnostic thresholds of the OGTT in treating GDM and pregnancy outcome viz. birth weight and perinatal mortality needs to be resolved for our community.

We determined the optimal screening method for GDM in a community based study at primary care level (using capillary whole blood) and the optimal use of the OGTT for confirming the diagnosis of GDM in an institutional based setting at tertiary care level (using venous plasma and a three point OGTT).

COMMUNITY BASED SCREENING FOR GDM

Method

A community survey was conducted using multi-stage cluster sampling to determine the proportion of pregnant women registered by the public health midwives (PHM) in the Homagama DHDS area (rural), which revealed that 99.6% of pregnant women registered before the 14th week of period of amenorrhoea (POA). All pregnant women registered for antenatal care between 1st April 2003 and 30th July 2003, excluding those with established glucose intolerance, were subjected to selected screening tests that were validated against the 75 g OGTT (gold standard) performed using capillary blood at POA of 24–28 weeks. Venous whole blood

¹Professor in Reproductive Medicine, ²Senior Registrar in Community Medicine, ³Demonstrators in Obstetrics and Gynaecology, Department of Obstetrics and Gynaecology, Faculty of Medicine, University of Colombo, Sri Lanka.

⁴Professor, Department of Community Medicine, Faculty of Medical Sciences, University of Sri Jayawardhena.

Correspondence: CNW, e-mail: <mandika59@hotmail.com> (Competing interests: none declared). Funding of community-based study: World Health Organization. Received 11 October 2005 and accepted 17 October 2006.
glucose estimation was carried out using Accutrend®
alpha glucometer immediately after blood sampling. We
validated this method against the standard laboratory
venous plasma glucose (PG) measurement prior to the
study and found that the two sets of measurements were
comparable (p > 0.05). A further 5% sub-sample of cap-
illary blood glucose assessments performed in the field
was validated against the corresponding venous blood
samples collected simultaneously. The diagnosis of
GDM was made based on WHO recommendations for
capillary and venous diagnostic criteria (Table 1) [6],
where the venous sample values measured using a labo-
ratory autoanalyser were considered as the gold stan-
dard. The preliminary results indicated that diagnosis of
GDM made based on capillary blood glucose 2 hour
post glucose load (2 hBG) had a sensitivity of 100% and
specificity of 100% when compared to that of the stan-
dard autoanalyser method.

### Results

Of 1036 pregnant women who fulfilled eligibility
criteria sixteen refused, and from 1020 who entered
the study 56 were lost to follow up, yielding a nonpartic-
ipation rate of 1.5% and loss to follow up rate of 5.5%. Of
964 study subjects 91 reported an abortion (9.4%) before
the OGTT at 24–28 weeks, and yet another 20 (2%) were
unable to tolerate an oral glucose load, thus yielding 853
women who completed both phases of the study. Table 2
shows the validity of individual

### Table 1. Values for diagnosis of diabetes mellitus and other categories of hyperglycaemia
(WHO recommendations, 1999) (Reference 6)

<table>
<thead>
<tr>
<th>Glucose concentration, mmol/l (mg/dl)</th>
<th>Whole blood venous</th>
<th>Whole blood capillary</th>
<th>Plasma* venous</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting</td>
<td>≥6.1 (≥110)</td>
<td>≥6.1 (≥110)</td>
<td>≥7.0 (≥126)</td>
</tr>
<tr>
<td>2-h post-glucose load</td>
<td>≥10.0 (≥180)</td>
<td>≥11.1 (≥200)</td>
<td>≥11.1 (≥200)</td>
</tr>
<tr>
<td>Impaired glucose tolerance (IGT)</td>
<td>&lt;6.1 (&lt;110) and</td>
<td>&lt;6.1 (&lt;110) and</td>
<td>&lt;7.0 (&lt;126)</td>
</tr>
<tr>
<td>Fasting (if measured)</td>
<td>≥6.7 (≥120) and</td>
<td>≥7.8 (≥140) and</td>
<td>≥7.8 (≥140) and</td>
</tr>
<tr>
<td>2-h post-glucose load</td>
<td>&lt;10.0 (&lt;180)</td>
<td>&lt;11.1 (≥200)</td>
<td>&lt;11.1 (&lt;200)</td>
</tr>
<tr>
<td>Impaired fasting glycaemia (IFG)</td>
<td>≥5.6 (≥100) and</td>
<td>≥5.6 (≥100) and</td>
<td>≥6.1 (≥110) and</td>
</tr>
<tr>
<td>Fasting</td>
<td>&lt;6.1 (&lt;110)</td>
<td>&lt;6.1 (&lt;110)</td>
<td>&lt;7.0 (&lt;126)</td>
</tr>
<tr>
<td>2-h post-glucose load</td>
<td>&lt;6.7 (&lt;120)</td>
<td>&lt;7.8 (&lt;140)</td>
<td>&lt;7.8 (&lt;140)</td>
</tr>
</tbody>
</table>

*Corresponding values for capillary plasma are: for Diabetes Mellitus, fasting ≥7.0 (≥126), 2-h ≥ 12.2 (≥220); for Impaired Glucose Tolerance, fasting <7.0 (<126) and 2-h ≥ 8.9 (<160) and <12.2 (<220); and for Impaired Fasting Glycaemia ≥6.1 (≥110) and <7.0 (<126) and if measured, 2-h <8.9 (<160)

1²Accutrend alpha® glucometer, which was validated against the enzymatic colorimetric assay that showed a sensitivity and specificity of 100%

2Enzymatic colorimetric assay (Hitachi, Roche), with intra-assay coefficient of variation (CV) of 1.9% and 1.7%; and inter-assay coefficient of variation (CV) of 1.9% L and 3.4% at glucose values of 363.6 mg/dl and at 43.2 mg/dl, respectively

### Table 2. Validity of the screening tests for GDM performed at 24–28 weeks of POA in the community survey

<table>
<thead>
<tr>
<th>Screening test</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
<th>Positive predictive value (%)</th>
<th>Negative predictive value (%)</th>
<th>Likelihood ratio of a positive test</th>
<th>Likelihood ratio of a negative test</th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) Random urinary Benedict's test</td>
<td>10.4</td>
<td>99.2</td>
<td>54.8</td>
<td>92.8</td>
<td>13.0</td>
<td>0.9</td>
</tr>
<tr>
<td>(b) Random urinary Dipstick test</td>
<td>16.6</td>
<td>98.8</td>
<td>55.0</td>
<td>93.3</td>
<td>13.7</td>
<td>0.8</td>
</tr>
<tr>
<td>*Postprandial urinary Benedict's test</td>
<td>52.2</td>
<td>94.5</td>
<td>46.3</td>
<td>96.1</td>
<td>9.5</td>
<td>0.5</td>
</tr>
<tr>
<td>*Postprandial urinary Dipstick test</td>
<td>68.7</td>
<td>90.4</td>
<td>38.0</td>
<td>97.1</td>
<td>7.2</td>
<td>0.3</td>
</tr>
<tr>
<td>Fasting capillary blood glucose cut-off 4.1 mmol/l (74 mg/dl)***</td>
<td>62.6</td>
<td>73.0</td>
<td>16.6</td>
<td>95.7</td>
<td>2.3</td>
<td>0.5</td>
</tr>
<tr>
<td>Presence of risk factors proposed by ADA <strong>Post-glucose capillary BG cut-off 7.2 mmol/l (130 mg/dl)</strong>*</td>
<td>93.1</td>
<td>22.2</td>
<td>9.9</td>
<td>97.1</td>
<td>1.2</td>
<td>0.3</td>
</tr>
<tr>
<td>98.5</td>
<td>95.2</td>
<td>64.0</td>
<td>99.9</td>
<td>20.5</td>
<td>0.02</td>
<td></td>
</tr>
</tbody>
</table>

*Urine sample taken two hours after the ingestion of standard 75 g glucose load
**Capillary blood sample taken two hours after ingesting 75 g glucose load
***Cut-off values determined using ROC curve

Ceylon Medical Journal
screening tests used for detecting GDM at 24–28 weeks of POA.

HOSPITAL BASED CONFIRMATION OF GDM WITH 75 g OGTT

(a) How predictive is the fasting plasma glucose?

The objective of this component of the study was to determine the sensitivity, specificity and predictive value of fasting plasma glucose (FPG) of the OGTT in diagnosing GDM.

Method

High risk women were screened by performing the 75 g 2 hour OGTT in the unit’s laboratory the morning after an overnight fast of at least 8 hours and not exceeding 14 hours, and following at least 3 days of unrestricted carbohydrates (>150 g per day) and exercise as per WHO guidelines [6]. The OGTT was performed between 24 and 28 weeks POA by taking whole venous blood at 0 hours (before) and 1 and 2 hours after ingestion of glucose. Plasma glucose was tested using an enzymatic colorimetric assay (Hitachi, Roche). A plasma glucose concentration at 2 hours when >7.8 mmol/l (140 mg/dl) was considered to confirm GDM as per WHO criteria, provided there was a peak rise at 1 hour.

We analysed retrospectively 999 consecutive OGTTs performed on pregnant women with risk factors who presented to the antenatal clinic, University Unit, De Soysa Hospital for Women from April 2003 to November 2003. Those in whom the 2-hour plasma glucose exceeded the 1 hour value (lag curve) were excluded.

Results

116/999 subjects (11.6%) had a lag curve and were excluded and the analysis confined to 883 data sets. 144/883 (16.3%) patients had an abnormal OGTT based on WHO criteria, of whom 4 (2.6%) had a FPG >7 mmol/l (126 g/dl) and 24 (16.7%) had a FPG >6.1 mmol/l (110 mg/dl). The sensitivity and specificity for different concentrations of FPG are shown in Table 3.

(b) What should be the threshold of the two-hour plasma glucose of the 75 g OGTT to predict the need for insulin treatment in Sri Lankans with GDM?

The objective of this component of the study was to determine the predictive value of the 2 hour plasma glucose (2hPG) concentration of the abnormal 75 g OGTT in Sri Lankan pregnant diabetics.

Method

We randomly selected pregnant women identified during the current gestation with 2hPG >7.8 mmol/l (140 mg/dl) in the 75 g OGTT (WHO criteria) and attending the specialist diabetic clinic at De Soysa Hospital for Women University Unit, Colombo between March–June 2003. They were studied prospectively for their serial 6-point plasma glucose profile over 24 hours, their maternal diabetic management requirements (viz. dietary restriction alone or diet combined with insulin), and pregnancy outcome (viz. perinatal mortality and birth weight). The need for antenatal insulin injections based on serial plasma glucose profiles after dietary modification, were matched against the 2hPG value of the OGTT performed between 24–28 weeks gestation. Their demographic data, family history, pregnancy outcome and birth weight were recorded.

Results

Sixty-six randomly selected women with abnormal OGTT were studied. 45 (68%) had a 2hPG ≥8.9 mmol/l (160 mg/dl), of whom 37 (82%) required insulin therapy during pregnancy and 8 were managed on dietary intervention alone. Of the 21 women with 2hPG <8.9 mmol/l one woman (4.8%) required insulin. The 2hPG value of the OGTT at a threshold of 8.9 mmol/l had a sensitivity of 97.2%, specificity of 71.4%, positive predictive value of 82.2% and negative predictive value of 95.2%. Table 4 shows the predictive values of 2hPG in

<table>
<thead>
<tr>
<th>Cut-off value for FPG (mmol/l)</th>
<th>Specificity</th>
<th>1-Specificity</th>
<th>Sensitivity</th>
<th>Positive predictive value</th>
<th>Negative predictive value</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.0 (126)</td>
<td>1</td>
<td>0</td>
<td>0.035</td>
<td>1</td>
<td>0.842</td>
</tr>
<tr>
<td>6.1 (110)</td>
<td>0.997</td>
<td>0.003</td>
<td>0.167</td>
<td>0.923</td>
<td>0.86</td>
</tr>
<tr>
<td>5.8 (105)</td>
<td>0.993</td>
<td>0.007</td>
<td>0.25</td>
<td>0.878</td>
<td>0.872</td>
</tr>
<tr>
<td>5.6 (100)</td>
<td>0.978</td>
<td>0.022</td>
<td>0.313</td>
<td>0.738</td>
<td>0.89</td>
</tr>
<tr>
<td>5.3 (95)</td>
<td>0.946</td>
<td>0.054</td>
<td>0.4792</td>
<td>0.633</td>
<td>0.903</td>
</tr>
<tr>
<td>5.0 (90)</td>
<td>0.852</td>
<td>0.148</td>
<td>0.618</td>
<td>0.45</td>
<td>0.92</td>
</tr>
<tr>
<td>4.7 (85)</td>
<td>0.687</td>
<td>0.313</td>
<td>0.792</td>
<td>0.33</td>
<td>0.944</td>
</tr>
<tr>
<td>4.4 (80)</td>
<td>0.461</td>
<td>0.539</td>
<td>0.903</td>
<td>0.246</td>
<td>0.961</td>
</tr>
<tr>
<td>4.2 (75)</td>
<td>0.191</td>
<td>0.809</td>
<td>0.972</td>
<td>0.19</td>
<td>0.972</td>
</tr>
<tr>
<td>3.9 (70)</td>
<td>0.045</td>
<td>0.955</td>
<td>1</td>
<td>0.17</td>
<td>1</td>
</tr>
</tbody>
</table>
Table 4. Predictive value of the two hour plasma glucose of the 75 g OGTT for needing insulin therapy for GDM in mmol/l (mg/dl)

<table>
<thead>
<tr>
<th>2 h PG value of OGTT (mmol/l)</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
<th>Positive predictive value (%)</th>
<th>Negative predictive value (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.8 (140)</td>
<td>100</td>
<td>26.2</td>
<td>60.8</td>
<td>100</td>
</tr>
<tr>
<td>8.3 (150)</td>
<td>97.9</td>
<td>40.5</td>
<td>65.3</td>
<td>94.4</td>
</tr>
<tr>
<td>8.9 (160)</td>
<td>35.8</td>
<td>61.9</td>
<td>74.2</td>
<td>92.9</td>
</tr>
<tr>
<td>9.4 (170)</td>
<td>83.3</td>
<td>78.6</td>
<td>81.6</td>
<td>80.5</td>
</tr>
</tbody>
</table>

Table 5. Maternal characteristics and pregnancy outcome in women treated with insulin and dietary modification alone (Student t test, p value significant <0.05)

<table>
<thead>
<tr>
<th></th>
<th>Dietary and modification insulin (n = 38)</th>
<th>Dietar y and modification alone (n = 28)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average maternal age (years)</td>
<td>32.23 ± 1.55</td>
<td>32.31 ± 1.37</td>
<td>0.94</td>
</tr>
<tr>
<td>History of diabetes in first degree relatives</td>
<td>18 (47.4%)</td>
<td>14 (50%)</td>
<td>0.67</td>
</tr>
<tr>
<td>Average birth weight (g)</td>
<td>3036 ± 230</td>
<td>2992 ± 168</td>
<td>0.75</td>
</tr>
<tr>
<td>Perinatal deaths</td>
<td>0</td>
<td>1*</td>
<td></td>
</tr>
</tbody>
</table>

*Had 2 hPG < 8.9 mmol/l

Discussion

The underlying assumption that justifies screening programmes for GDM is that early detection and effective control of hyperglycaemia during pregnancy leads to significant reduction in both maternal and perinatal morbidity and mortality [7–9]. The WHO recommends universal screening of pregnant women with the OGTT as the screening test as well as the confirmatory test for GDM [6]. The American Diabetes Association (ADA) recommends the 1 hour glucose challenge test (GCT) as a screening test, and the positives to be followed up with the 100 g 3 hour OGTT [2]. We previously reported that the GCT had lower predictive value as a screening test than conventional risk factor identification in a hospital based study in Colombo, Sri Lanka [10].

Our maternal and child health (MCH) system needs to be recommended a screening test with a reasonably high degree of sensitivity, specificity and positive predictive value that is less expensive, non invasive and more acceptable, which could be implemented through the prevailing MCH infrastructure. This would enable universal screening for GDM when subjects positive for the screening test need to be subjected to the diagnostic OGTT. The ideal screening test for GDM should possess a relatively high sensitivity because the penalty associated with missing a case is high since definitive and effective treatment is available. However, increasing the sensitivity of a test invariably compromises its specificity leading to a relatively higher proportion of false positives. If the proportion of false positives is very high the whole purpose of screening will negate the sustainability of the screening programme.

Screening methods recommended by the WHO and ADA are invasive, time consuming, need technically competent personnel, and laboratory and transport facilities that are expensive. The interpretation of laboratory screening tests for GDM are confounded by the changes in maternal carbohydrate metabolism during normal pregnancy, viz. a greater propensity to renal glycosuria and lactosuria, the maternal state of accelerated starvation causing lowering of blood glucose in the fed and fasting states, delayed gastric emptying leading to lag curves of the OGTT, increased insulin resistance after 24 weeks of gestation [11], and the blood sample and laboratory test method used to determine blood/plasma glucose concentrations (Table 1) [6].

**COMMUNITY BASED SCREENING FOR GDM**

Our national MCH system currently performs the Benedict’s test for random glycosuria to screen for GDM at every antenatal visit. When we validated this test against the OGTT, it yielded a sensitivity of 10% or would have missed 90% of subjects with GDM (false negatives), while 45% of the positive tests did not have GDM (false positives). Hence, the Benedict’s test has poor sensitivity and is an unacceptable screening test for GDM. The use of semi-quantitative enzyme based test strips (Dipstick®) to detect glycosuria gave a marginal benefit of a sensitivity of 16.4%. The sensitivity of detecting glycosuria was improved to some extent by using postprandial urine samples. When Benedict’s test to detect postprandial glycosuria was validated, it reported a sensitivity of 52.2% and a false negative rate of 47.8%, while 53.7% of positive results did not have GDM (false positives). Validating the postprandial glycosuria Dipstick® test reported a sensitivity of 68.7% and a false positive rate of 62%. Hence, testing for postprandial glycosuria is better than testing for random glycosuria in the screening for GDM, as previously reported [12]. When we compared the likelihood ratio of a negative result between the two urinary tests, the post-prandial Dipstick® test was superior with a lower value (0.3) when compared to the postprandial Benedict’s test (0.5). However, its moderate sensitivity and relatively high false positive rate negates its use as the ideal universal screening tool for GDM.

The WHO and ADA do not advocate using fasting blood glucose (FBG) as a screening test for GDM. Hence,
we first calculated the appropriate threshold for FBG by using the receiver operator characteristic (ROC) curve, which was 4.1 mmol/l (74 mg/dl). When we validated FBG of 4.1 mmol/l to detect GDM, it reported a sensitivity of 62.6%, a false negative rate of 37.4%, and false positive rate of 83.4% making it unsuitable as a screening test. Risk factors associated with GDM if proven valid will offer a simple screening method for GDM. Screening with selectivity criteria proposed by ADA [2] revealed a sensitivity of 93.1%, false negative rate of only 6.9%, but a high false positive rate of 90.1%. Hence, using risk factors as a screening test, without additional cost or effort, could prevent 21% of this population being exposed to the invasive and costly OGTT. Nevertheless, its drawback is its high false positive rate. The WHO and ADA do not advocate using postprandial (after a 75 g standard glucose load) blood sugar test (2hBG) alone as a screening test for GDM. Hence, we first calculated the appropriate cut-off value by using the ROC curve method, and the calculated threshold was 7.2 mmol/l (130 mg/dl). Validating capillary 2hBG at a threshold of 7.2 mmol/l to detect GDM reported a sensitivity of 98.5%, a specificity of 95.2% i.e. true negatives and a false positive rate of 36%.

In summary, this community based study demonstrates that capillary blood glucose 2 hours following 75 g glucose loading validates satisfactorily against the OGTT, while all other screening tests are ineffective at field level. This also confirms that the current screening practice adopted in our MCH system is suboptimal. Testing for postprandial glycosuria by enzyme based test strips might be a better alternative, at least for an interim period, until our MCH system is able to implement optimal screening. Selecting mothers for OGTT based on risk factors proposed by ADA can be implemented without additional cost through our MCH system. Its main drawback is that nearly 80% of pregnant women will have to undergo diagnostic OGTT; which makes the cost and effort similar to implementing universal screening by OGTT as proposed by WHO. We therefore propose capillary post 75 g glucose test at a diagnostic threshold of 7.2 mmol/l (130 mg/dl) as the ideal screening test to be applied at 24–28 weeks of POA in the field setting. In view of its 36% false positive rate leading to subjects with a positive result having to undergo an unwarranted OGTT, it is essential to conduct an in depth cost analysis to prove that this test has an advantage over universal screening with OGTT.

HOSPITAL BASED CONFIRMATION OF GDM WITH 75 g OGTT

When compared with most other endocrine diagnostic procedures the 75 g OGTT is relatively less expensive, less invasive and more acceptable particularly when limited to three plasma glucose estimations at 0 hours prior to glucose loading and at 1 and 2 hours post glucose loading. The false positives of the initial screening tool can thereby be excluded and the true positives appropriately managed, which has been the routine practice over the previous decade in our maternity unit based in a tertiary care setting in Colombo. It is appropriate to review our experience with the 75 g OGTT in terms of its applicability to all health care institutions of the country, and in helping towards optimising its usefulness in the diagnosis and management of GDM. Issues that need to be resolved are to identify the minimum number of blood tests required to be performed in an OGTT, and the predictive value of test results in terms of instituting insulin therapy in the antenatal care of the affected woman.

(a) How predictive is the fasting plasma glucose?

ROC showed the accuracy of FPG as satisfactory with an area under the curve of 0.84 that yielded a satisfactory sensitivity and specificity at a threshold value of 4.7 mmol/l (85 mg/dl) [Figure 1]. However, lowering the FPG threshold increases the sensitivity but reduces specificity and positive predictive value. Perucchini et al [13], who recommended the cut off for FPG as 4.8 mmol/l (87 mg/dl) and Reichelt et al [14], who recommended FPG cut off as 4.7 mmol/l reported a sensitivity around 80% when validated against 3 hour 100 g OGTT. Their findings mirror our experience with the hospital based 75 g OGTT. The even lower threshold for fasting blood glucose measured in our community based study is likely to be due to red cell utilization of whole blood glucose and the dilution effect of body fluids as reflected in lower diagnostic values for diabetes by capillary whole blood testing compared to venous plasma glucose as depicted in Table 1. Our finding that the value of fasting plasma glucose in diagnosing GDM although improved by lowering the threshold to 4.6 mmol/l (84 mg/dl) has a specificity of only 68.7%, leads us to question its actual need when performing the 75 g OGTT. Furthermore, these results reveal that testing the 2-hour post 75 g plasma glucose alone as suggested by others from a similar setting [15] would involve a 12% risk of false positives caused by delayed absorption in pregnancy. Therefore we recommend replacing the fasting plasma glucose test of the 75 g OGTT with the 1 hour glucose estimation, and thereby limit hospital based screening in the laboratory setting to only two tests.
(b) What should be the threshold for the two-hour plasma glucose of the 75 g OGTT to predict the need for insulin treatment among Sri Lankans with GDM?

We reported in 1997 that the 2-hour post 75 g OGTT plasma glucose exceeding 8.9 mmol/l in a hospital based cohort was more predictive of GDM than the 50 g glucose challenge test [16]. The current prospective study on the treatment requirements of GDM in relation to the 2 h plasma glucose concentration of the 75 g OGTT performed at 24–28 weeks pregnancy is in keeping with YonTen’s previous reports, in that the threshold value at 8.9 mmol/l is a good predictor of the need for insulin when managing GDM which leads to a satisfactory pregnancy outcome.

In conclusion, we recommend that in primary care screening for GDM, testing for postprandial glycosuria by enzyme based test strips is a better alternative to the current practice of Benedict’s test of random urine, until our MCH system is able to implement universal screening using capillary blood glucose 2 hours following 75 g glucose loading at 24–28 weeks of pregnancy in the field, following an in depth survey of its cost effectiveness. We also recommend that to confirm gestational diabetes in the hospital laboratory setting the 75 g OGTT be restricted to two plasma glucose tests performed 1 and 2 hours after glucose loading, and that the 2-hour plasma glucose concentration exceeds 8.9 mmol/l (160 mg/dl) following a one hour peak it should alert the health care teams to a high probability of the need for insulin to maintain maternal normoglycemia in order to achieve satisfactory pregnancy outcome.

Acknowledgements

Director National Institute of Health Sciences, Kalutara, WHO (for funding), DDHS, MOH, Public Health Nursing Sisters, Public Health Midwives of Homagama DDHS area for their ready support in the community based project.

Head, academic staff, consultants and support staff of the Department of Obstetrics and Gynaecology, Faculty of Medicine, University of Colombo, Sri Lanka; Director and administrative staff of De Soysa Hospital for Women, Colombo, Sri Lanka; Mrs Sumedha Wijeratne, Senior Lecturer in charge, and Laboratory Technical Officers Mrs ASDS Wijeratne, Mrs AUA Gunewardhena and Mrs M Warnakulasuriya for laboratory support.

All pregnant women for their ready co-operation.

References


